4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia

European Journal of Immunology

Volumn 42, Issue 3, 2012, Pages 737-748

  Buechele, Corina ^a   Baessler, Tina ^a   Schmiedel, Benjamin J ^a   Schumacher, Carla E ^a   Grosse Hovest, Ludger ^a   Rittig, Kilian ^a   Salih, Helmut R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cell surface molecules; Chronic lymphocytic leukemia (CLL); NK cells; TNF family; Tumor immunity

Indexed keywords

CD137 LIGAND; INFLIXIMAB; TUMOR NECROSIS FACTOR;

ARTICLE; CELL INTERACTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNOREGULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

4-1BB LIGAND; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859495391     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141920     Document Type: Article

References (43)

1. Vivier, E., Tomasello, E., Baratin, M., Walzer, T. and Ugolini, S., Functions of natural killer cells. Nat. Immunol. 2008. 9: 503-510.
2. Caligiuri, M. A., Human natural killer cells. Blood 2008. 112: 461-469.
3. Keating, G. M., Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010. 70: 1445-1476.
4. Weiner, G. J., Rituximab: mechanism of action. Semin. Hematol. 2010. 47: 115-123.
5. Beck, A., Wurch, T., Bailly, C. and Corvaia, N., Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010. 10: 345-352.
6. Clynes, R. A., Towers, T. L., Presta, L. G. and Ravetch, J. V., Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000. 6: 443-446.
7. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. and Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002. 99: 754-758.
8. Weng, W. K. and Levy, R., Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003. 21: 3940-3947.
9. Jaglowski, S. M., Alinari, L., Lapalombella, R., Muthusamy, N. and Byrd, J. C., The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010. 116: 3705-3714.
10. Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M. and Ugolini, S., Innate or adaptive immunity? The example of natural killer cells. Science 2011. 331: 44-49.
11. Ljunggren, H. G. and Malmberg, K. J., Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 2007. 7: 329-339.
12. Watts, T. H., TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 2005. 23: 23-68.
13. Lynch, D. H., The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol. Rev. 2008. 222: 277-286.
14. Lin, W., Voskens, C. J., Zhang, X., Schindler, D. G., Wood, A., Burch, E., Wei, Y. et al., Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. Blood 2008. 112: 699-707.
15. Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S. and Chen, L., NK1. 1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998. 190: 167-172.
16. Baessler, T., Charton, J. E., Schmiedel, B. J., Grunebach, F., Krusch, M., Wacker, A., Rammensee, H. G. and Salih, H. R., CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010. 115: 3058-3069.
17. +cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. 2002. 169: 4230-4236.
18. Shao, Z. and Schwarz, H., CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J. Leukoc. Biol. 2011. 89: 21-29.
19. Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Muller, A. M. et al., CD137 stimulation enhances the anti-lymphoma activity of anti-CD20 antibodies. Blood 2010. 117: 2423-2432.
20. Palma, C., Binaschi, M., Bigioni, M., Maggi, C. A. and Goso, C., CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival. Int. J. Cancer 2004. 108: 390-398.
21. Salih, H. R., Kosowski, S. G., Haluska, V. F., Starling, G. C., Loo, D. T., Lee, F., Aruffo, A. A. et al., Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J. Immunol. 2000. 165: 2903-2910.
22. Eissner, G., Kolch, W. and Scheurich, P., Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 2004. 15: 353-366.
23. Ferrajoli, A., Keating, M. J., Manshouri, T., Giles, F. J., Dey, A., Estrov, Z., Koller, C. A. et al., The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002. 100: 1215-1219.
24. Wierda, W. G., Johnson, M. M., Do, K. A., Manshouri, T., Dey, A., O'Brien, S., Giles, F. J. et al., Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br. J. Haematol. 2003. 120: 452-456.
25. Weng, W. K., Negrin, R. S., Lavori, P. and Horning, S. J., Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 2010. 28: 279-284.
26. Dunn, G. P., Old, L. J. and Schreiber, R. D., The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004. 22: 329-360.
27. Zitvogel, L., Tesniere, A. and Kroemer, G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006. 6: 715-727.
28. Croft, M., The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 2009. 9: 271-285.
29. +T cells and inhibit tumor growth in mice. J. Clin. Invest 2008. 118: 376-386.
30. Yang, Y., Yang, S., Ye, Z., Jaffar, J., Zhou, Y., Cutter, E., Lieber, A. et al., Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res. 2007. 67: 2339-2344.
31. Baessler, T., Krusch, M., Schmiedel, B. J., Kloss, M., Baltz, K. M., Wacker, A., Schmetzer, H. M. and Salih, H. R., Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res. 2009. 69: 1037-1045.
32. Baltz, K. M., Krusch, M., Bringmann, A., Brossart, P., Mayer, F., Kloss, M., Baessler, T. et al., Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 2007. 21: 2442-2454.
33. Placke, T., Kopp, H. G. and Salih, H. R., Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin. Dev. Immunol. 2010. 2010: 239083.
34. Levings, M. K., Sangregorio, R., Sartirana, C., Moschin, A. L., Battaglia, M., Orban, P. C. and Roncarolo, M. G., Human CD25+CD4+T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 2002. 196: 1335-1346.
35. Baltz, K. M., Krusch, M., Baessler, T., Schmiedel, B. J., Bringmann, A., Brossart, P. and Salih, H. R., Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein (GITR) ligand increases NK cell anti-tumor reactivity. Blood 2008. 112: 3735-3743.
36. Liu, B., Li, Z., Mahesh, S. P., Pantanelli, S., Hwang, F. S., Siu, W. O. and Nussenblatt, R. B., GITR negatively regulates activation of primary human NK cells by blocking proliferative signals and increasing NK cell apoptosis. J. Biol. Chem. 2008. 283: 8202-8210.
37. Binsky, I., Haran, M., Starlets, D., Gore, Y., Lantner, F., Harpaz, N., Leng, L. et al., IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc. Natl. Acad. Sci. USA 2007. 104: 13408-13413.
38. Sethi, G., Sung, B., Kunnumakkara, A. B. and Aggarwal, B. B., Targeting TNF for treatment of cancer and autoimmunity. Adv. Exp. Med. Biol. 2009. 647: 37-51.
39. Oflazoglu, E. and Audoly, L. P., Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010. 2: 14-19.
40. Woyach, J. A., Lin, T. S., Lucas, M. S., Heerema, N., Moran, M. E., Cheney, C., Lucas, D. M. et al., A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009. 23: 912-918.
41. Salih, H. R., Schmetzer, H. M., Burke, C., Starling, G. C., Dunn, R., Pelka-Fleischer, R., Nuessler, V. and Kiener, P. A., Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J. Immunol. 2001. 167: 4059-4066.
42. Armour, K. L., Clark, M. R., Hadley, A. G. and Williamson, L. M., Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur. J. Immunol. 1999. 29: 2613-2624.
43. Witthauer, J., Schlereth, B., Brischwein, K., Winter, H., Funke, I., Jauch, K. W., Baeuerle, P. and Mayer, B., Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110. Breast Cancer Res. Treat. 2009. 117: 471-481.